EMG
MRNS

Ellington Management Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Ellington Management Group’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,125
Closed -$330K – 1062
2017
Q4 		$330K Sell
10,125
-1,150
-10% -$31K 0.05% 337
2017
Q3 		$265K Buy
+11,275
New +$126K 0.05% 433

Other funds holding MRNS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
TBC
Three Bays Capital Boston, Massachusetts $848M AUM 7.41% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ellington Management Group's MRNS Position: Q1 2018 in Review

Ellington Management Group sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2018, closing a stake of 10,125 shares — an estimated $330K sold.

Ellington Management Group first reported a position in MRNS in Q3 2017 and held it in 2 quarters. The position peaked at $330K in Q4 2017. 60 funds tracked by Wall St. Rank hold MRNS as of Q1 2018.

  • Ellington Management Group reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2018 after selling out during the quarter.
  • Ellington Management Group sold 10,125 Marinus Pharmaceuticals, Inc shares in Q1 2018, an estimated $330K.
  • Ellington Management Group first reported a position in Marinus Pharmaceuticals, Inc in Q3 2017 and held it in 2 quarters.
  • Ellington Management Group's Marinus Pharmaceuticals, Inc position peaked at $330K in Q4 2017.
  • 60 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2018.

Based on Ellington Management Group's 13F filing for Q1 2018, filed 15 May 2018.